Tacrolimus Modulates Peripheral Blood NK Cell Subsets and IL ‐17/ IL ‐10 Ratio in Women With Recurrent Implantation Failure
Reproductive Medicine and Biology · 2026-01 · 25 (1)
DOI: 10.1002/rmb2.70083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproductive Medicine and Biology, online erschienen am 02.08.2026. Verfasst von Marzieh Zamaniyan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, IVF Ward, Faculty of Medicine Imam Khomeini Hospital, Mazandaran University of Medical Sciences Sari Iran. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Mazandaran University of Medical Sciences.
Abstract (Originalsprache)
Purpose
Recurrent implantation failure (RIF) is linked to immune dysregulation. Although tacrolimus has shown clinical benefits in RIF, its immunological mechanisms remain unclear. We assessed its effects on peripheral blood NK cell subsets and cytokine profiles.
Methods
Thirty women with RIF and 30 fertile controls were enrolled. Patients received oral tacrolimus (3 mg/day) before embryo transfer until pregnancy testing. NK cell subsets and IL‐17/IL‐10 expression were assessed by flow cytometry and real‐time PCR before and after treatment.
Results
At baseline, RIF patients showed higher NK cell‐associated subsets and increased IL‐17/IL‐10 ratio compared with controls (CD16 + : p = 0.019; CD56 + : p < 0.0001; CD16 + CD56 + : p < 0.0001; IL‐17/IL‐10 ratio: p < 0.0001). Following tacrolimus, CD16 + ( p = 0.011), CD56 + ( p = 0.001), and CD16 + CD56 + ( p = 0.001) NK cells, as well as IL‐17 levels ( p < 0.0001) and the IL‐17/IL‐10 ratio ( p = 0.0036), were significantly reduced, whereas IL‐10 expression remained unchanged ( p = 0.406). Greater reductions in the IL‐17/IL‐10 ratio were associated with clinical pregnancy ( p = 0.048), suggesting predictive value for implantation success.
Conclusions
Tacrolimus modulated immune pathways by reducing pro‐inflammatory NK subsets and shifting the IL‐17/IL‐10 balance toward tolerance, supporting its potential as targeted immunotherapy in selected patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, IVF Ward, Faculty of Medicine Imam Khomeini Hospital, Mazandaran University of Medical Sciences Sari Iran.
- Sexual and Reproductive Health Research Center Imam Khomeini Hospital, Mazandaran University of Medical Sciences Sari Iran.
- Thalassemia Research Center Mazandaran University of Medical Sciences Sari Iran.
- Department of Immunology, School of Medicine Mazandaran University of Medical Sciences Sari Iran.
- Molecular and Cell Biology Research Center Mazandaran University of Medical Sciences Sari Iran.
ORCID-Profile: Marzieh Zamaniyan, Imaneh Ahmadi, Mohammad Malekan, Hossein Asgarian-Omran, Saeid Taghiloo
Förderung
- Mazandaran University of Medical Sciences
Zitieren
APA
Zamaniyan, M., Peivandi, S., Ahmadi, I., Ghasemzadeh, F., Malekan, M., Bahri, B., Lotfi, M., Asgarian-Omran, H., & Taghiloo, S. (2026). Tacrolimus Modulates Peripheral Blood NK Cell Subsets and IL ‐17/ IL ‐10 Ratio in Women With Recurrent Implantation Failure. Reproductive Medicine and Biology, 25(1). https://doi.org/10.1002/rmb2.70083
Vancouver
Zamaniyan M, Peivandi S, Ahmadi I, Ghasemzadeh F, Malekan M, Bahri B, et al. Tacrolimus Modulates Peripheral Blood NK Cell Subsets and IL ‐17/ IL ‐10 Ratio in Women With Recurrent Implantation Failure. Reproductive Medicine and Biology. 2026;25(1). doi:10.1002/rmb2.70083
BibTeX
@article{Zamaniyan2026,
author = {Zamaniyan, Marzieh and Peivandi, Sepideh and Ahmadi, Imaneh and Ghasemzadeh, Fatemeh and Malekan, Mohammad and Bahri, Behshad and Lotfi, Maryam and Asgarian-Omran, Hossein and Taghiloo, Saeid},
title = {Tacrolimus Modulates Peripheral Blood NK Cell Subsets and IL ‐17/ IL ‐10 Ratio in Women With Recurrent Implantation Failure},
journal = {Reproductive Medicine and Biology},
year = {2026},
volume = {25},
number = {1},
doi = {10.1002/rmb2.70083}
}
EUVIMED